top of page

Banner_OffTargetEffectswithMattGline[92].png

Off Target Effects with Matt Gline

About the show: Matt shares a biotech CEO's perspective on the news, and he interviews other leaders about management topics important to navigating the business of drug development.

About Matt

Matt Gline serves as Chief Executive Officer of Roivant Sciences. Mr. Gline joined Roivant in March 2016 and previously served as Chief Financial Officer. From April 2014 to March 2016, he was a Vice President at Goldman Sachs, Fixed Income Digital Structuring, where he focused on technology and data strategy.

Prior to Goldman Sachs, Mr. Gline was a co-founder of Fourthree, a risk analytics technology and consulting company. From 2008 to 2012, he served as Vice President at Barclays, Enterprise Risk Management Advisory, where he provided analysis for corporate clients related to capital markets access for financing and risk management. Mr. Gline earned his A.B. in Physics from Harvard College.

Episodes

Off-Target Effects Episode 7: Perceptive Advisors' Joe Edelman discusses how biotech investing has changed over his extensive career, and his thoughts on running an investment firm | 06/25/26

Episode 7: Perceptive Advisors' Joe Edelman discusses how biotech investing has changed over his extensive career, and his philosophy on running an investment firm

Off-Target Effects Episode 6: BridgeBio Founder & CEO Neil Kumar discusses the hub and spoke biotech model and trying to build a sustainable business for the long-term | 04/23/26

Episode 6: BridgeBio Founder & CEO Neil Kumar discusses the hub and spoke biotech model and trying to build a sustainable business for the long-term

Off-Target Effects Episode 5: John Maraganore has been a champion of innovation throughout his career. He discusses the road to success at Alnylam, today's environment, and keeping the U.S. on top | 04/09/26

Episode 5: John Maraganore has been a champion of innovation throughout his career. He discusses the road to success at Alnylam, today's environment, and keeping the U.S. on top

Off-Target Effects Episode 4: Matt speaks with Philip Ross, one of the most experienced and successful bankers in healthcare, about the M&A landscape and his decision to join Jefferies last year | 04/30/25

Episode 4: Philip Ross, one of the most experienced and successful bankers in healthcare, on the M&A landscape and his decision to join Jefferies last year

Off-Target Effects Episode 3: Matt speaks with STAT News' Adam Feuerstein about the dynamics of biotech journalism and how it compares to other industries | 05/08/25

Episode 3: STAT News' Adam Feuerstein describes the dynamics of biotech journalism and how it compares to other industries

Off-Target Effects Episode 2: Matt speaks with Avoro Capital's Behzad Aghazadeh about the hot button issues that have been striking the biotech sector | 04/10/25

Episode 2: Matt speaks with Avoro Capital's Behzad Aghazadeh about the hot button issues that have been striking the biotech sector

Off Target Effects Episode 1: From SF Healthcare Week, Matt interviews Brad Loncar about M&A and China's impact on it | 01/16/25

Episode 1: From SF Healthcare Week, Matt interviews Brad Loncar about M&A and China's potential impact on it

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

10x_Genomics_logo.svg.png

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

bottom of page